Members of the NCRI Brain Group have published a position statement arguing that there is not enough evidence to support…
COVIDSurg gathers evidence on the safety of surgery during COVID-19
'The COVID-19 pandemic resulted in rapid reductions in elective surgery, including surgery as a treatment for head and neck cancer.…
Identifying lymphoma treatment response using molecular profiling
'Diffuse large B cell lymphoma (DLBCL) is an aggressive B cell malignancy and the most common type of non-Hodgkin lymphoma.…
Study identifies challenges in involving young people in research
'Evaluating specialist care for young people with cancer was identified as a research priority by the NCRI Teenage and Young…
Using knowledge provided by NCRI research funding data to increase the impact of prostate cancer research
'Prostate Cancer Research recognised that with a large number of cancer research charities duplication was a possibility and that challenges…
Strengthening the research workforce through NCRI Group membership
'Dr Simon Mitchell is a member of the Science Subgroup of the NCRI Lymphoma Group and has recently been awarded…
NCRI Lymphoma Group member receives UKRI fellowship
'Congratulations to Dr Simon Mitchell, who is a member of the Science Subgroup of the NCRI Lymphoma Group, on being…
Developing one of the most extensive global studies of lung cancer patients
'Could tumour diversity be resulting in poor treatment outcomes? Despite many years of clinical research into lung cancer, the outcomes…
Artificial intelligence can help to improve prognosis and treatment for glioblastoma
'In the first study of its kind in cancer, researchers have applied artificial intelligence to measure the amount of muscle…
Making informed decisions in the event of myeloma relapse
'Treating relapsed myeloma Around 5,700 people are diagnosed with myeloma in the UK each year. As there is no cure…
Establishing a resource for chronic lymphocytic leukaemia researchers
'Biobanks give researchers access to biological material and clinical data on a scale that individual researchers would not be able…
Interview with Diana Jupp, CEO, Pancreatic Cancer UK
'Why did Pancreatic Cancer UK want to become NCRI partners? For decades, too little progress has been made in pancreatic…